These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25850767)

  • 41. [Treatment of systemic sclerosis-associated interstitial lung disease].
    Prasse A; Bonella F; Müller-Ladner U; Witte T; Hunzelmann N; Distler J
    Z Rheumatol; 2020 Apr; 79(3):294-303. PubMed ID: 31754786
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Strategy for treatment of fibrosis in systemic sclerosis: Present and future.
    Yanaba K
    J Dermatol; 2016 Jan; 43(1):46-55. PubMed ID: 26782006
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
    Maier C; Ramming A; Bergmann C; Weinkam R; Kittan N; Schett G; Distler JHW; Beyer C
    Ann Rheum Dis; 2017 Jun; 76(6):1133-1141. PubMed ID: 28209630
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
    Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systemic sclerosis-related pulmonary hypertension: unique characteristics and future treatment targets.
    Dimitroulas T; Giannakoulas G; Karvounis H; Settas L; Kitas GD
    Curr Pharm Des; 2012; 18(11):1457-64. PubMed ID: 22364130
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise?
    Antic M; Distler JH; Distler O
    Curr Opin Pharmacol; 2013 Jun; 13(3):455-62. PubMed ID: 23747024
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting TLRs and the inflammasome in systemic sclerosis.
    Henderson J; Bhattacharyya S; Varga J; O'Reilly S
    Pharmacol Ther; 2018 Dec; 192():163-169. PubMed ID: 30081049
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Induction of Inflammation and Fibrosis by Semaphorin 4A in Systemic Sclerosis.
    Carvalheiro T; Affandi AJ; Malvar-Fernández B; Dullemond I; Cossu M; Ottria A; Mertens JS; Giovannone B; Bonte-Mineur F; Kok MR; Marut W; Reedquist KA; Radstake TR; García S
    Arthritis Rheumatol; 2019 Oct; 71(10):1711-1722. PubMed ID: 31012544
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Peroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis.
    Wei J; Bhattacharyya S; Varga J
    Curr Opin Rheumatol; 2010 Nov; 22(6):671-6. PubMed ID: 20693905
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeted therapies for systemic sclerosis.
    Denton CP; Ong VH
    Nat Rev Rheumatol; 2013 Aug; 9(8):451-64. PubMed ID: 23567456
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phototherapy in systemic sclerosis: Review.
    Chaowattanapanit S; Choonhakarn C; Foocharoen C; Julanon N
    Photodermatol Photoimmunol Photomed; 2017 Nov; 33(6):296-305. PubMed ID: 28703365
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New pathogenic and therapeutic concepts in systemic sclerosis.
    Hügle T; Huigens CA; van Laar JM
    Arzneimittelforschung; 2009; 59(12):615-24. PubMed ID: 20108646
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Emerging targeted therapies in scleroderma lung and skin fibrosis.
    Maurer B; Distler O
    Best Pract Res Clin Rheumatol; 2011 Dec; 25(6):843-58. PubMed ID: 22265265
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recent advances in the diagnosis and treatment of systemic sclerosis.
    Kowal-Bielecka O; Bielecki M; Kowal K
    Pol Arch Med Wewn; 2013; 123(1-2):51-8. PubMed ID: 23344666
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CD8+ T cells in systemic sclerosis.
    Fuschiotti P
    Immunol Res; 2011 Aug; 50(2-3):188-94. PubMed ID: 21717073
    [TBL] [Abstract][Full Text] [Related]  

  • 56. B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis.
    Daoussis D; Tsamandas A; Antonopoulos I; Filippopoulou A; Papachristou DJ; Papachristou NI; Andonopoulos AP; Liossis SN
    Arthritis Res Ther; 2016 May; 18(1):118. PubMed ID: 27208972
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Autoimmunity in systemic sclerosis: current concepts.
    Boin F; Rosen A
    Curr Rheumatol Rep; 2007 May; 9(2):165-72. PubMed ID: 17502048
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
    Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
    Front Immunol; 2020; 11():1990. PubMed ID: 33013852
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Systemic sclerosis: an update.
    Varga J
    Bull NYU Hosp Jt Dis; 2008; 66(3):198-202. PubMed ID: 18937632
    [TBL] [Abstract][Full Text] [Related]  

  • 60. T cells and cytokines in systemic sclerosis.
    Fuschiotti P
    Curr Opin Rheumatol; 2018 Nov; 30(6):594-599. PubMed ID: 30234723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.